This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

It’s been a rough year for the NASDAQ Composite Index (NASDAQINDEX: ^IXIC), plunging nearly 30% this year. While part of this sell-off was certainly warranted (as 2021’s valuations couldn’t be sustained), some stocks have sold off too much.

Here are three stocks I’m looking at buying as their long-term opportunities are still intact while their share prices are well off their highs: Alphabet Inc. (NASDAQ: GOOG), MercadoLibre, Inc. (NASDAQ: MELI), and CrowdStrike Holdings, Inc. (NASDAQ: CRWD). Stick around to find out why.

Alphabet

Alphabet (formerly known as Google) is a huge conglomerate of businesses, but its primary focus is advertising. In good times, this business shines. Unfortunately, in bad times, advertising can be a rough business to be in.

When companies are forced to cut costs to maintain profits, advertising budgets are often the first thing to go. It’s an easy cut compared to laying off workers or canceling projects, so many companies do it pre-emptively if they see signs of a slowing economy. This line of thinking harmed Alphabet in the second quarter, but it still managed to grow revenue by 13% year over year.

That resiliency shows how vital it is for businesses to advertise on Alphabet’s family of businesses (like the Google search engine, Android operating system, or YouTube).

Despite rising expenses (which caused Alphabet’s profitability to drop), Alphabet trades at a historically low 18.6 times earnings. That’s dirt cheap for a company whose revenue has always recovered after economic downturns.

GOOG Revenue (Quarterly YoY Growth) data by YCharts.

I’m confident that this slowdown will be like the rest, and Alphabet’s revenue growth will recover to higher levels, bringing its strong cash flows higher with it.

MercadoLibre

Another internet powerhouse, MercadoLibre, is based in Latin America. Serving 18 countries — home to about 650 million people — MercadoLibre brings many facets of e-commerce that Americans take for granted to Latin America.

With fintech and commerce platforms, consumers can shop on Mercado Libre (the commerce site) and pay with Mercado Pago (its payment platform) while using the credit card they got through Mercado Credito (its credit division). Then, the package may arrive on the customer’s doorstep in less than 48 hours after being delivered by Mercado Envios (its logistics division). Nearly 80% of packages it handled were delivered in under 48 hours in Q2.  

MercadoLibre is the e-commerce site in Latin America, and for good reason. Backing up its market dominance are its results, which were fantastic in Q2.

Revenue rose 57% year over year to $2.6 billion, driven by strength in fintech, which grew revenue 107% to $1.2 billion. Commerce is facing tougher comparisons (thanks to a COVID-affected 2021 Q2) but still grew revenue by 23% year over year while its gross merchandise volume rose 26%. While not massively profitable, MercadoLibre still posted a 4.7% profit margin in Q2.

With those results, you might expect the stock to be up significantly this year or to at least break even. However, the shares are down 34%, and the valuation sits at five times sales. The last time MercadoLibre was this cheap was at the depth of the Great Recession in 2009.

MercadoLibre has traded around 12 times sales for nearly all of the past decade, so this stock is incredibly cheap. As a result, I believe MercadoLibre is one of the strongest no-brainer buys in the market today.

CrowdStrike

While the first two stocks are cheaply valued, CrowdStrike is not. Instead, it trades for a hefty 21 times sales.  Still, I think it’s an excellent buy today because of its market opportunity and sustained, strong execution.

CrowdStrike is a cybersecurity company, and with the cost of cyberattacks expected to grow 15% annually through 2025, it’s an area that businesses can’t afford to cut corners on now. With its cloud-based platform, CrowdStrike’s software can quickly deploy to network endpoints (like phones or laptops). Its software uses artificial intelligence and machine learning to evolve the program continuously, so when one customer experiences an attack, the entire customer base’s defense is strengthened through that information.

While many companies have slowed their enterprise software spending, CrowdStrike managed to grow its customer base by 51% in Q2 (ended July 31) to 19,686. Among these customers are 69 of the Fortune 100 and 537 of the Global 2000, showing that CrowdStrike still has many customers to capture, especially smaller businesses worldwide.

Annually recurring revenue (ARR) also rapidly increased in Q2, rising 59% year over year to $2.14 billion. Still, this is a drop in the bucket compared to CrowdStrike’s projected $126 billion market opportunity in 2025.

While CrowdStrike may be an expensive stock, its massive market opportunity and strong growth are the culprits of this valuation. Unfortunately, the best companies don’t often come cheap, so investors sometimes pay a premium to own a specific business. However, if CrowdStrike’s growth continues on its strong trajectory (management projects ARR will be $5 billion by January 2026), the price that investors are paying today will seem much cheaper.

The NASDAQ has multiple great investment opportunities available now; investors just need the confidence to step in and buy stocks when everything seems to be looking grim.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

The post 3 stocks I’m buying during the NASDAQ bear market appeared first on The Motley Fool Australia.

More reading

• This stock market investment strategy made money 100% of the time over the last century
• Is Google really trying to buy Pinterest?
• Here’s why splitting up Amazon could mean huge returns for shareholders
• Could Canva spoil the party of these giant tech stocks?
• Amazon, Microsoft, and Alphabet have partnered with this US cloud stock. Is it a buy?

Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool’s board of directors. Keithen Drury has positions in Alphabet (C shares), CrowdStrike Holdings, Inc., and MercadoLibre. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Alphabet (A shares), Alphabet (C shares), CrowdStrike Holdings, Inc., and MercadoLibre. The Motley Fool Australia has recommended Alphabet (A shares), Alphabet (C shares), and CrowdStrike Holdings, Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

from The Motley Fool Australia https://ift.tt/k3bZxr8

The CogState Limited (ASX: CGS) share price is having a sensational day.

In morning trade, the neuroscience technology company’s shares were up as much as 61% to $2.26 before being halted.

Why is the CogState share price rocketing higher?

Investors have been bidding the CogState share price higher today despite there being no news out of the company.

However, it is worth noting that its partner, Japan’s Eisai, has released some very big news today.

According to NBC, the Japanese drugmaker’s experimental drug for Alzheimer’s disease has helped slow cognitive decline in patients in the early stages of the illness.

The company said that in a phase 3 clinical trial of lecanemab, cognitive decline was slowed by 27% after 18 months. These results were based on 1,795 patients, who were randomly assigned to receive either the drug or a placebo every two weeks over the months.

Though, it is worth noting that these results have not yet been peer-reviewed.

What does this have to do with CogState?

This could be very good news for CogState.

In August 2019, Cogstate entered into an exclusive licensing agreement with Eisai. This agreement saw Eisai market Cogstate technologies as digital cognitive assessment tools in the Japanese market.

In October 2020, the two parties then extended the agreement to the rest of the world in a US$45 million deal.

Trading halt

Investors won’t have to wait long for an explanation for the rampant rise today. It appears as though the high flying CogState share price has caught the attention of the Australian stock exchange.

As a result, the company’s shares have been paused pending the release of a further announcement.

The post Why is the CogState share price rocketing 61% higher today? appeared first on The Motley Fool Australia.

More reading

• Top broker says this ASX tech share has over 30% upside
• 3 ASX All Ordinaries shares being sold off following FY22 results

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CogState Limited. The Motley Fool Australia has positions in and has recommended CogState Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/JKAhOvt

The time has come for Coles Group Ltd (ASX: COL) shareholders to check their bank accounts today.

The supermarket giant is paying out its latest dividend to those who scooped up its shares before 2 September.

Coles is rewarding eligible shareholders with a fully franked dividend of 30 cents per share.

At the time of writing, the Coles share price is $16.51, down 1.02%. For context, the S&P/ASX 200 Index (ASX: XJO) is up 0.2% to 6,509 points.

Let’s take a look at all the details regarding the company’s dividend.

Coles pays out its latest dividend

Coles reported a relatively resilient performance in its full-year results despite being impacted by inflationary pressures.

In summary, sales revenue lifted by 2% to $39.4 billion over the prior corresponding period. This was driven by the strong sales growth of its Supermarkets segment (+12%), Liquor (+18%), and Express (+8.1%).

Management noted that “domestic product availability is steadily improving whilst the international supply chain remains more volatile due to the ongoing shipping disruptions and the conflict in Ukraine”.

On the bottom line, Coles achieved a net profit after tax (NPAT) of around $1.05 billion, up 4.3%.

Subsequently, the board elected to increase its final dividend by 7.1% from the 28 cents per share in FY 2021.

Based on today’s price, Coles has a current dividend yield of 3.83%.

Coles share price snapshot

The Coles share price is down 8% in 2022, but flat when factoring in the last 12 months.

Its shares hit a 52-week high of $19.65 last month before plummeting 15% on the back of its 2022 financial results.

Coles has a price-to-earnings (P/E) ratio of 21.19 and commands a market capitalisation of roughly $22.31 billion.

The post The Coles dividend is hitting bank accounts today. Here’s what you need to know appeared first on The Motley Fool Australia.

More reading

• Broker names 2 ASX dividend shares to buy with ~7% yields
• Market volatility getting you down? Analysts name 2 defensive ASX 200 shares to buy
• Is the Coles share price a defensive ASX 200 buy right now?
• Top brokers name 3 ASX shares to buy next week
• Brokers name 3 ASX shares to buy today

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended COLESGROUP DEF SET. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/zak2uGV

AMP Ltd (ASX: AMP) might present a curious case for investors. On the one hand, it has committed to return capital to shareholders through share buybacks, but it did not declare a dividend in 1H FY22.

So why did the financial services company decide on this course of action?

One explanation is that AMP had other priorities. A focus for the first half of FY22 was to pay down debt on its balance sheet. It allocated $400 million for this purpose from the $1.5 billion total surplus capital for the reported period.

However, some analysts have forecast changes to AMP’s capital position. Bloomberg analysts Matt Ingram and Jack Baxter believe AMP will successfully sell off some of its assets and then reroute the funds back to investors in the form of dividends later this year.

An AMP dividend still might be a possibility for FY22

The Bloomberg analysts believe AMP will not only resume paying dividends, but its dividend yield will be considerably higher than previous forecasts.

The pair said:

AMP may achieve 15% dividend yield this year vs. consensus’ 3%, despite stating it’s not in a position to resume regular payouts to ‘hold a strong capital position’. This curbs our expected A$1 billion 2022 payout and more than 20% yield. Yet yield will get a boost on its plan to return a majority of proceeds from the sale of Collimate Capital businesses, which we think could top A$500 million.

While this prediction did not come to fruition in 1H FY22, we have the rest of the year to go, so its final results may surprise investors.

In the meantime, AMP will continue to buy back its shares from the market until June 2023. Last month, the company announced it will buy $350 million worth of its shares as part of a $1.1 billion capital return package.

AMP share price snapshot

The AMP share price is up more than 10% year to date. Meanwhile, the S&P/ASX 200 Index (ASX: XJO) is down around 13% over the same period.

Shares in the company are currently trading for $1.1025 apiece, down 1.12%, while the benchmark index is up 0.2% in early morning trading.

AMP has a market capitalisation of around $3.61 billion.

The post Why is AMP doing a share buyback but not paying dividends? appeared first on The Motley Fool Australia.

More reading

• AMP share price slips ahead of court findings
• Are AMP shares worth keeping?
• Here are the 3 most heavily traded ASX 200 shares on Monday
• When it comes to AMP shares, is it time for investors to give up the ghost?
• Savings or dividends? What these 3 ASX bank shares are offering for income

Motley Fool contributor Matthew Farley has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/edETYQv

1) Overnight, the S&P 500 Index (SP: .INX) fell for the sixth session in a row, the longest losing streak since February 2020. It has fallen 7.8% so far in September, living up to its “worst month of the year” reputation. 

There’s nothing more that markets hate than uncertainty, and with interest rates across the globe rising at some of the fastest rates in decades in order to tame inflation, we’ve got it in spades.

“Right now there’s a lot of variables up in the air and we’re not going back and forth between optimism and pessimism — there’s a legitimate repricing and re-evaluation going on at the moment,” said Shawn Cruz, head trading strategist at TD Ameritrade, on Bloomberg. 

2) Here in Australia, the S&P/ASX 200 Index (ASX: XJO) is finally showing signs of cracking, having lost 6.7% so far in September, bringing its year to date losses to a chunky 12.7%.

Big losers so far this year include popular tech stocks Megaport Ltd (ASX: MP1), Block Inc (ASX: SQ2) and Xero Limited (ASX: XRO), down 57%, 52% and 44% respectively.

Although the ASX 200 is having a tough year, it has got nothing on the falls seen in US markets, with the S&P 500 down 23.5% so far in 2022 and the NASDAQ-100 Index (NASDAQ: NDX) off 30.8% in the same period.

Huge gains in coal stocks – with Whitehaven Coal (ASX: WHC) and New Hope Corporation Limited (ASX: NHC) up 224% and 157% respectively this year – have saved the day for the ASX 200, with hot lithium stocks Core Lithium Ltd (ASX: CXO) and Sayona Mining Ltd (ASX: SYA) not far behind, up 102% and 77% respectively so far in 2022.

3) Speaking of coal stocks, writing on Livewire, Steve Johnson of Forager Funds says, using current spot prices, some coal companies “are generating almost their whole market cap every year in cash flow.” 

Coal companies mentioned in this category include Yancoal Australia Ltd (ASX: YAL) and Coronado Global Resources Inc (ASX: CRN). 

The market is of course assuming coal prices won’t stay this high forever, but in the meantime, investors can pocket some very juicy dividends. As ever, there are no free lunches in investing, and the old saying “if it looks too good to be true it usually is” rings true. Whilst the trailing dividends are very attractive, given the coal price is likely to fall over time, the risk of capital loss is elevated.

4) Whilst many investors are in a world of hurt in this tough year, ASX lithium stocks are partying like supply for the battery-making material will never catch up to demand as the transition to electric vehicles rolls inexorably onwards.

Broker JP Morgan recently said it expected a lithium supply shortfall to last until 2025, whilst Piedmont Lithium (ASX: PLL) CEO Keith Phillips effectively said he expects the shortfall to last until 2035.

That said, not everyone shares in the enthusiasm for lithium stocks. 

Writing in its August monthly update, the Spheria Australian Microcap Fund said it feels the risk-reward equation for Sayona Mining investors is unfavorable, given the company’s near $3 billion (at the time) market capitalisation, considering first spodumene production is expected in 2023 and first refined product is planned by 2025.

The fund also noted fellow lithium stock Liontown Resources Limited (ASX: LTR) – with a market capitalisation (at the time) of close to $4 billion – has no revenue with first production expected in late FY24.

“We feel the lithium price is trading well ahead of fundamentals and there are risks with investing in this kind of project given the timeline to production and large valuation already ascribed by the market,” said the fund.

The Liontown Resources share price has actually fallen 9% so far in 2022.

The post September living up to its ‘worst month of the year’ reputation as ASX 200 finally cracks appeared first on The Motley Fool Australia.

More reading

• Why is everyone talking about pricing power and which ASX shares have it?
• Broker names 2 high yield ASX 200 dividend shares to buy
• Here are the top 10 ASX 200 shares today
• Why are these ASX lithium miners powering up today?
• Why Core Lithium, Ramsay, Synlait Milk, and Virgin Money shares are dropping

Motley Fool contributor Bruce Jackson has positions in Xero and Block. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended MEGAPORT FPO and Xero. The Motley Fool Australia has positions in and has recommended Xero. The Motley Fool Australia has recommended MEGAPORT FPO. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/bmEorsT

When markets turn sour, investors tend to flock towards ‘safe-haven’ assets in an attempt to preserve wealth. In the past, gold has been the go-to during these times of instability.

Yet, if the past year has been anything to go by, perhaps healthcare shares included in the S&P/ASX 200 Index (ASX: XJO) are the new ‘gold standard’.

Seeking out healthier returns than the ASX 200

Historically, the eye-catching yellow metal has delivered superior returns throughout periods of high inflation.

According to a recent article from Australian Resources and Investment, the price of gold rose an average of 14% when inflation was above 3%. Similarly, the precious metal achieved returns of almost 25% (on average) during bouts of inflation averaging above 5%.

That would lead investors to believe that gold exposure would be ideal amid the highest annual inflation we have seen in decades.

However, the price of gold per ounce has moved nearly 7% downward compared to a year ago.

Furthermore, the lack of protection extends over to ASX-listed gold mining shares. Even the biggest of the big have suffered tremendously in the last 12 months.

As shown below, the likes of Northern Star Resources Ltd (ASX: NST), Newcrest Mining Ltd (ASX: NCM), and Evolution Mining Ltd (ASX: EVN) have cratered 28.5%, 37.8%, and 55.6%, respectively. Whereas, a handful of ASX 200 healthcare shares have managed to hold up better and, in some cases, outperform.

While the returns might still be negative, the point is the reduced downside. Investments in Cochlear Limited (ASX: COH), ResMed Inc (ASX: RMD), and CSL Limited (ASX: CSL) have resulted in more modest falls of 18.6%, 6.3%, and 2.8%, respectively.

Yesterday, Janus Henderson portfolio manager Andy Acker highlighted some attractive traits of healthcare companies.

With interest rates expected to keep rising and economic growth potentially slowing, the pricing power and non-cyclicality of areas such as pharmaceuticals and managed care could continue to stand out.

Is there still value in gold as a hedge?

Despite the lacklustre performance of gold and gold mining shares, could there still be a case for holding these ‘traditionally’ inflation-hedged assets?

Firstly, the precious metal may have yielded a negative return in the last year. However, as demonstrated in the chart below, it has still outperformed the ASX 200 index. That alone could be justification that gold still has its protective properties.

For now, investors of gold mining shares will be hoping their luck soon turns. These companies are currently struggling with a double whammy. Simultaneously, gold prices are falling while input costs — such as labour and materials — are increasing.

The post Move over gold: Could ASX 200 healthcare shares be the new ‘safe-haven’ investments? appeared first on The Motley Fool Australia.

More reading

• Experts name 2 star blue chip ASX 200 shares to buy now
• ‘Long term view’: Expert names 2 punished ASX shares with ‘bright outlook’
• Here are the top 10 ASX 200 shares today
• Not all ASX 200 shares are getting hammered today. Here are some winners
• Why this expert has a ‘positive long-term view’ on the CSL share price

Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd., Cochlear Ltd., and ResMed Inc. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed Inc. The Motley Fool Australia has recommended Cochlear Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/JzZFXkn

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is taking a tumble on Wednesday.

In morning trade, the therapeutic radiopharmaceuticals company’s shares are down 12% to $4.74.

Why is the Telix share price sinking?

Investors have been selling down the Telix share price on Wednesday following the release of a disappointing announcement relating to its European aspirations.

According to the release, the company has withdrawn its marketing authorisation application (MAA) in Europe for its investigational product Illuccix.

Management advised that during the late stages of review, the Danish Medicines Agency (DKMA), in consultation with other European regulatory authorities, requested additional Chemistry, Manufacturing and Control (CMC) data.

Unfortunately, as these requests cannot be reasonably delivered within the prescribed review timeframe, Telix elected to withdraw the application.

This has come as big surprise to both investors and the company. Telix highlights that it was “an unexpected and extremely disappointing result considering that Illuccix has been approved by other major global regulators.”

It also highlights that the company has a “track record of delivering PSMA PET imaging reliably and safely to tens of thousands of European men with prostate cancer under compassionate and “magisterial” use availability.”

What’s next?

Telix intends to resubmit for a marketing authorisation for Illuccix in Europe. It is also assessing alternative regulatory options available for the most streamlined route to approval with a revised submission

Telix CEO, Dr Christian Behrenbruch, commented:

This is not the outcome we expected, despite our best efforts to meet all regulator information requests. The outcome is reflective of the novelty of our submission approach (‘full mixed’ application) and the specific nuances of European product approval requirements (EU Pharmacopoeia). We are confident that the additional data can be provided, but the prescribed timeframes of the review process mean that the most efficient process is to withdraw the application and then resubmit.

We note that the financial impact for FY2023 is minimal as full commercial sales were not expected to commence until mid-2023, following completion of the national approval phase and securing individual country reimbursement. We are in the fortunate position of having commercial sales underway in the United States and Australia, where we expect to see the growth trajectory continue. We remain committed to bringing an approved 68Ga-PSMA-11 product to market in Europe.

But it wasn’t all bad news today. In a separate announcement, Telix revealed that the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation has approved a pivotal Phase III registration study.

This study will bridge to Telix’s global Phase III ‘ZIRCON’ trial of TLX250-CDx for the imaging of clear cell renal cell carcinoma (ccRCC) with position emission tomography (PET).

The post Telix share price sinks 12% on European blow appeared first on The Motley Fool Australia.

More reading

• 3 hot small-cap ASX growth shares Firetrail’s backing right now
• 2 healthcare ASX shares ready to go off like a cracker: experts

Motley Fool contributor James Mickleboro has positions in TELIXPHARM DEF SET. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/S0Ljk8E

The Bubs Australia Ltd (ASX: BUB) share price won’t be going anywhere on Wednesday.

That’s because prior to the market open this morning, the junior infant formula company requested a trading halt.

What’s going on with the Bubs share price?

The Bubs share price has been halted this morning at the company’s request.

According to the release, Bubs has requested that its shares remain halted until the earlier of the release of an announcement or the commencement of trade on Friday 30 September.

Shareholders will no doubt be wondering what this announcement relates to. And while information is scant at this stage, the company revealed that it does relate to its Chinese operations.

The company’s trading halt request states:

the trading halt is requested pending an announcement by Bubs regarding a new joint venture arrangement for the manufacture and distribution of Bubs’ branded products in China.

Given that the company has already signed a major distribution deal with a key diagou seller in the region, this news is a little out of left field.

So, investors will have to sit tight and see what exactly is going on once the announcement is made.

And with the Bubs share price down almost 20% since this time month, shareholders will no doubt be hoping that this announcement is the catalyst to getting it heading in the right direction once again.

The post Bubs share price halted amid JV news from China appeared first on The Motley Fool Australia.

More reading

• How do A2 Milk shares stack up against Bubs post-earnings season?
• Why Bell Potter is tipping 40% upside for the Bubs share price
• Why Bravura, Bubs, Grange, and Sandfire shares are sinking
• Why is the Bubs share price down 4% after reporting strong FY22 growth?
• Bubs share price on watch as full-year revenue blasts 127% higher

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended BUBS AUST FPO. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/izh8dHy

Are you looking for exchange traded funds (ETFs) to buy? If you are, then you may want to look at the two exciting ETFs that are listed below.

Here’s why they could be worth getting better acquainted with:

BetaShares Crypto Innovators ETF (ASX: CRYP)

If you believe that cryptocurrencies are more than a fad and here to stay for the long term, then you may want to consider an investment in the BetaShares Crypto Innovators ETF.

That’s because this high risk ETF provides investors with exposure to the companies that are heavily involved in the industry.

This includes mining equipment manufacturers, trading platform providers, cryptocurrency miners, and companies holding cryptocurrencies on their balance sheet.

Among the shares you’ll be owning a slice of if you buy this ETF are crypto mining hardware manufacturer Canaan, crypto trading platform Coinbase, crypto bank Silvergate, and crypto miner Riot Blockchain.

BetaShares Global Cybersecurity ETF (ASX: HACK)

Another exciting ETF for ASX investors to consider making an investment in is the BetaShares Global Cybersecurity ETF.

This ETF is certainly a topical choice given the recent hack at Optus. While it’s unclear how sophisticated that attack actually was, it is a reminder that companies and consumers need to invest in cybersecurity services to ensure they and their assets are protected online.

It is also worth highlighting that this was by no means the only attack that occurred this month. Both Rockstar Games and Uber have recently been breached by hackers and you can bet that countless smaller companies have also felt their wrath.

In light of this, it wouldn’t be surprising if the growing demand for cybersecurity services went up a gear in the near term.

This bodes well for the companies included in the HACK ETF such as Accenture, Cisco, Cloudflare, Crowdstrike, Fortinet, Okta, and Splunk.

The post Don’t miss out on these very exciting ASX ETFs appeared first on The Motley Fool Australia.

More reading

• 2 excellent ETFs for ASX investors to buy now
• Could the HACK ETF provide a hedge against future cyber fallout?
• These could be 2 of the most exciting ETFs for ASX investors to buy
• Don’t miss out on these high quality ASX ETFs
• 2 excellent ETFs for ASX investors to buy this month

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended BETA CYBER ETF UNITS and Betashares Crypto Innovators ETF. The Motley Fool Australia has positions in and has recommended BETA CYBER ETF UNITS. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/kMAtiZg

It’s been a big couple of months for ASX dividend investors. 

According to CommSec, companies in the S&P/ASX 200 Index (ASX: XJO) declared more than $42 billion worth of dividends in the recent ASX reporting season.

Now, a lot of these ASX 200 shares are turning ex-dividend, taking away entitlements to their upcoming dividend payments.

But a particular subset of ASX 200 shares will be in focus tomorrow: real estate investment trusts (REITs).

See, ASX REITs typically pay quarterly dividends (also known as distributions). And within the last couple of weeks, many have declared their distributions for the quarter ending 30 September 2022. 

Tomorrow, more than a dozen ASX REITs will be going ex-dividend. And in the process, taking their unfranked dividends off the table.

Five, in particular, are members of the ASX 200 index. Let’s check them out.

Charter Hall Long WALE REIT (ASX: CLW)

The largest ASX REIT by market capitalisation going ex-dividend tomorrow is the Charter Hall Long WALE REIT.

This REIT focuses on high-quality real estate on long-term leases, investing in around 550 properties in Australia and New Zealand with long weighted average lease expiry (WALE) periods.

As of tomorrow, the Charter Hall Long WALE REIT will no longer trade with rights to receive a quarterly distribution payment of 7 cents on 11 November.

Pleasingly for investors, REITs often provide specific guidance for the year ahead. In terms of dividends, the CLW REIT is expecting to declare total distributions of 30.5 cents in FY23, up 4% from the prior year. This represents a dividend yield of 7.7%. 

HomeCo Daily Needs REIT (ASX: HDN)

Next up, HomeCo is another ASX 200 REIT turning ex-dividend tomorrow. This REIT focuses on convenience-based assets across the subsectors of neighbourhood retail, large format retail, and health and services. 

Think local town centres and shopping strips. Its top three tenants by gross income are Woolworths Group Ltd (ASX: WOW), Bunnings, and Coles Group Ltd (ASX: COL).

Tomorrow, HomeCo shares will be trading without entitlements to the latest quarterly distribution of 2.075 cents, which will be paid “on or about” 25 November. The REIT also has a dividend reinvestment plan (DRP) available.

Looking ahead, HomeCo is guiding for FY23 distributions of 8.3 cents, relatively in line with the most recent financial year. At current levels, this equates to a dividend yield of 7.3%.

Waypoint REIT Ltd (ASX: WPR)

The next cab off the rank is Waypoint, a REIT that focuses on petrol station assets around the country. Waypoint shares will be trading tomorrow without a quarterly distribution of 3.95 cents, which will be paid on 15 November.

Waypoint recently announced its first-half 2022 results, reiterating FY22 distribution guidance of 16.44 cents. This would be a 4% hike from the prior year and represents a dividend yield of 7.1%.

Centuria Industrial REIT (ASX: CIP)

Centuria Industrial is another ASX 200 REIT turning ex-dividend tomorrow. CIP is Australia’s largest domestic pure-play industrial REIT, with most of its 88 industrial assets located along the eastern seaboard of Australia.

Today will be the final day that the Centuria Industrial REIT will be trading with its latest quarterly distribution of 4 cents. For now, the REIT has flagged a payment date of 28 October.

In FY22, the Centuria Industrial REIT declared total distributions of 17.3 cents. The REIT is guiding for FY23 distributions of 16 cents, down 8% year over year, representing a dividend yield of 6.2% based on current prices.

Arena REIT (ASX: ARF)

Last but not least, the Arena REIT will also be trading ex-dividend tomorrow. This REIT focuses on social infrastructure properties, which are leased to a diversified tenant base in the childcare and healthcare sectors.

From tomorrow onwards, Arena will no longer be trading with its latest quarterly distribution of 4.2 cents. The payment date has been pencilled in for 3 November. A DRP is also available for shareholders who wish to participate.  

When announcing its full-year results last month, Arena provided FY23 distribution guidance of 16.8 cents. This would represent 5% growth from the prior year and spins up a dividend yield of 4.8%.

The post Here are 5 ASX 200 shares turning ex-dividend tomorrow appeared first on The Motley Fool Australia.

More reading

• Broker names 2 ASX dividend shares to buy with ~7% yields
• Boost your income with these ASX dividend shares: experts
• The biggest threats and opportunities for ASX industrial REITs revealed: fund manager
• Goldman Sachs names 2 ASX dividend shares to buy
• How this ASX 200 REIT is delivering 5% plus dividend yields: fund manager

Motley Fool contributor Cathryn Goh has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended COLESGROUP DEF SET. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/VpX9nz7